What question did this study set out to answer?

To evaluate the real-world efficacy, safety, and quality of life associated with once-weekly somatrogon for children with growth hormone deficiency.

March 19, 2026Open Access

Once-Weekly Somatrogon in Pediatric Growth Hormone Deficiency: Real-World Efficacy, Safety, and Quality-of-Life Findings

Key Points

To evaluate the real-world efficacy, safety, and quality of life associated with once-weekly somatrogon for children with growth hormone deficiency.
Case series analysis of children diagnosed with growth hormone deficiency
Comparison between once-weekly somatrogon and daily somatropin treatment
Assessment of quality of life and psychosocial outcomes
Somatrogon showed comparable efficacy to daily somatropin treatments
Safety profile of somatrogon was similar to that of conventional daily therapy
Quality of life and psychosocial outcomes remained stable during the treatment

Abstract

Once-weekly somatrogon demonstrated efficacy and safety comparable to daily somatropin with stable quality of life and psychosocial outcomes in children with GHD.

AIに質問

Bookmark

View Full Paper

Cite This Study

Küçük et al. (Mon,) studied this question.

synapsesocial.com/papers/69bb91c7496e729e6297f34b https://doi.org/https://doi.org/10.4274/jcrpe.galenos.2026.2025-11-4

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AIに質問

Bookmark

View Full Paper